vs
Side-by-side financial comparison of StoneX Group Inc. (SNEX) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 2.0× StoneX Group Inc.). Zoetis runs the higher net margin — 25.3% vs 11.6%, a 13.7% gap on every dollar of revenue. On growth, StoneX Group Inc. posted the faster year-over-year revenue change (81.0% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $-1.3B). Over the past eight quarters, StoneX Group Inc.'s revenue compounded faster (53.5% CAGR vs 4.4%).
StoneX Group Inc. is an American financial services company. The company operates in six areas: commercial hedging, global payments, securities, physical commodities, foreign exchange and clearing and execution services (CES).
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
SNEX vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $139.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 15.4% | 31.9% |
| Net Margin | 11.6% | 25.3% |
| Revenue YoY | 81.0% | 3.0% |
| Net Profit YoY | 63.3% | 3.8% |
| EPS (diluted) | $2.50 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $32.7B | $2.4B | ||
| Q2 25 | $851.2M | $2.5B | ||
| Q1 25 | $820.4M | $2.2B | ||
| Q4 24 | $663.1M | $2.3B | ||
| Q3 24 | $31.1B | $2.4B | ||
| Q2 24 | $571.8M | $2.4B | ||
| Q1 24 | $509.2M | $2.2B |
| Q4 25 | $139.0M | $603.0M | ||
| Q3 25 | $85.7M | $721.0M | ||
| Q2 25 | $63.4M | $718.0M | ||
| Q1 25 | $71.7M | $631.0M | ||
| Q4 24 | $85.1M | $581.0M | ||
| Q3 24 | $76.7M | $682.0M | ||
| Q2 24 | $61.9M | $624.0M | ||
| Q1 24 | $53.1M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | 3.7% | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | 3.0% | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 15.4% | 31.9% | ||
| Q3 25 | 0.3% | 37.0% | ||
| Q2 25 | -1.3% | 36.7% | ||
| Q1 25 | -1.0% | 36.5% | ||
| Q4 24 | -3.2% | 31.6% | ||
| Q3 24 | -0.0% | 36.6% | ||
| Q2 24 | -4.7% | 33.0% | ||
| Q1 24 | -2.5% | 34.1% |
| Q4 25 | 11.6% | 25.3% | ||
| Q3 25 | 0.3% | 30.0% | ||
| Q2 25 | 7.4% | 29.2% | ||
| Q1 25 | 8.7% | 28.4% | ||
| Q4 24 | 12.8% | 25.1% | ||
| Q3 24 | 0.2% | 28.6% | ||
| Q2 24 | 10.8% | 26.4% | ||
| Q1 24 | 10.4% | 27.4% |
| Q4 25 | $2.50 | $1.37 | ||
| Q3 25 | $0.72 | $1.63 | ||
| Q2 25 | $1.22 | $1.61 | ||
| Q1 25 | $1.41 | $1.41 | ||
| Q4 24 | $1.69 | $1.29 | ||
| Q3 24 | $2.32 | $1.50 | ||
| Q2 24 | $1.25 | $1.37 | ||
| Q1 24 | $1.09 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $3.3B |
| Total Assets | $47.8B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.3B | $2.0B |
| Q4 25 | $2.5B | $3.3B | ||
| Q3 25 | $2.4B | $5.4B | ||
| Q2 25 | $2.0B | $5.0B | ||
| Q1 25 | $1.9B | $4.7B | ||
| Q4 24 | $1.8B | $4.8B | ||
| Q3 24 | $1.7B | $5.2B | ||
| Q2 24 | $1.6B | $5.0B | ||
| Q1 24 | $1.5B | $5.1B |
| Q4 25 | $47.8B | $15.5B | ||
| Q3 25 | $45.3B | $15.2B | ||
| Q2 25 | $34.3B | $14.5B | ||
| Q1 25 | $31.3B | $14.1B | ||
| Q4 24 | $29.6B | $14.2B | ||
| Q3 24 | $27.5B | $14.4B | ||
| Q2 24 | $25.9B | $14.2B | ||
| Q1 24 | $25.7B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3B | $893.0M |
| Free Cash FlowOCF − Capex | $-1.3B | $732.0M |
| FCF MarginFCF / Revenue | -106.4% | 30.7% |
| Capex IntensityCapex / Revenue | 1.3% | 6.7% |
| Cash ConversionOCF / Net Profit | -9.08× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $3.5B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.3B | $893.0M | ||
| Q3 25 | $3.5B | $938.0M | ||
| Q2 25 | $1.5B | $486.0M | ||
| Q1 25 | $-154.5M | $587.0M | ||
| Q4 24 | $-477.8M | $905.0M | ||
| Q3 24 | $192.6M | $951.0M | ||
| Q2 24 | $-622.1M | $502.0M | ||
| Q1 24 | $784.0M | $595.0M |
| Q4 25 | $-1.3B | $732.0M | ||
| Q3 25 | $3.5B | $805.0M | ||
| Q2 25 | $1.5B | $308.0M | ||
| Q1 25 | $-169.8M | $438.0M | ||
| Q4 24 | $-491.4M | $689.0M | ||
| Q3 24 | $175.9M | $784.0M | ||
| Q2 24 | $-640.5M | $370.0M | ||
| Q1 24 | $766.6M | $455.0M |
| Q4 25 | -106.4% | 30.7% | ||
| Q3 25 | 10.7% | 33.5% | ||
| Q2 25 | 173.3% | 12.5% | ||
| Q1 25 | -20.7% | 19.7% | ||
| Q4 24 | -74.1% | 29.7% | ||
| Q3 24 | 0.6% | 32.8% | ||
| Q2 24 | -112.0% | 15.7% | ||
| Q1 24 | 150.5% | 20.8% |
| Q4 25 | 1.3% | 6.7% | ||
| Q3 25 | 0.1% | 5.5% | ||
| Q2 25 | 1.9% | 7.2% | ||
| Q1 25 | 1.9% | 6.7% | ||
| Q4 24 | 2.1% | 9.3% | ||
| Q3 24 | 0.1% | 7.0% | ||
| Q2 24 | 3.2% | 5.6% | ||
| Q1 24 | 3.4% | 6.4% |
| Q4 25 | -9.08× | 1.48× | ||
| Q3 25 | 41.18× | 1.30× | ||
| Q2 25 | 23.52× | 0.68× | ||
| Q1 25 | -2.15× | 0.93× | ||
| Q4 24 | -5.61× | 1.56× | ||
| Q3 24 | 2.51× | 1.39× | ||
| Q2 24 | -10.05× | 0.80× | ||
| Q1 24 | 14.76× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SNEX
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
